Brief: Chemours Q3 Adjusted EPS USD 0.4 Vs. IBES Estimate USD 0.28
04/11/2024 11:00
Nov 04 (Reuters) - Chemours Q3 adjusted EBITDA USD 208 million vs. IBES estimate USD 187.7 million. * Q3 adjusted net income USD 61 million vs. IBES estimate USD 44.4 million * Q3 sales USD 1,500 million vs. IBES estimate USD 1,442 million
Recent news on The Chemours
See all newsUS RESEARCH ROUNDUP-Essex Property Trust, Qualys, Vulcan Materials
3M, DuPont must face Connecticut firefighters' lawsuit over 'forever chemicals'
Chemours, DuPont, Corteva settle North Carolina 'forever chemicals' claims for $455 million
U.S. RESEARCH ROUNDUP-Argan, Mastec, Oracle
New Jersey's $2.5 billion 'forever chemicals' settlements with DuPont, 3M, others win court approval